A Phase I clinical trial of AMV-564 in patients with Myelodysplastic Syndrome (MDS)

Trial Profile

A Phase I clinical trial of AMV-564 in patients with Myelodysplastic Syndrome (MDS)

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs AMV 564 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2017 New trial record
    • 11 Sep 2017 According to an Amphivena Therapeutics media release, company plans to launch this clinical study in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top